A specialized, discovery stage biotech, developing novel and best-in-class therapies to treat Oncology & Inflammation >>More
Track-record of over 40 programs in collaboration with some of the leading global Pharma partners >>More
With about 500 scientists, Aurigene has developed
deep expertise in various target classes >>More
Aurigene and Orion Announce Research, Collaboration and Option Agreement for BET Inhibitors
Small research firms aim to change face of cancer therapy...
Aurigene Announces Licensing of its PD-1 Program to Pierre Fabre, France
18 Nov - 21 Nov 2014: 26th EORTC – AACR Sympsoium...